Natera, Inc.

Ucl Business Plc

University College London

The Francis Crick Institute Limited

Robert Charles Swanton

Christopher Abbosh

Bernhard Zimmermann

Huseyin Eser Kirkizlar

Tudor Pompiliu Constantin

Raheleh Salari

Nicholas McGranahan

Mariam Jamal-hanjani

Gareth Wilson

Dhruva Biswas

Nicolai Juul Birkbak

Mariam Jamal-Hanjani

The invention relates to subject-specific methods for detecting recurrence of tumours based on an understanding of the clonal/subclonal mutation profile of the subject's tumour and detection of the mutations in their cell-free DNA (cfDNA), typically by multiplex PCR of tumour mutations such as single nucleotide variants (SNVs).

Method of detecting tumour recurrence

The present invention provides a method for providing a prognosis for a subject with lung cancer, the method comprising: (a) contacting a biological sample from the subject with reagents that specifically bind to each member of a panel of biomarkers comprising ANLN, ASPM, CDCA4, ERRFI1, FURIN, GOLGA8A, ITGA6, JAG1, LRP12, MAFF, MRPS17, PLK1, PNP, PPP1 R13L, PRKCA, PTTG1, PYGB, RPP25, SCPEP1, SLC46A3, SNX7, TPBG, XBP1; (b) determining a riskscore of the subject based on the nucleic acid levels of expression of the biomarkers in the samples; and (c) providing a prognosis for the lung cancer based on the risk score of the subject.

Method of predicting survival rates for cancer patients

The invention provides methods for detecting single nucleotide variants in lung cancer, especially stage 3a lung adenocarcinoma and lung squamous cell carcinoma. Additional methods and compositions, such as reaction mixtures and solid supports comprising clonal populations of nucleic acids, are provided.

Methods for lung cancer detection

Growing community of inventors

London, United Kingdom

Robert Charles Swanton